Welcome to our dedicated page for Elicio Therapeutics news (Ticker: ELTX), a resource for investors and traders seeking the latest updates and insights on Elicio Therapeutics stock.
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company developing a pipeline of investigational cancer immunotherapies built on its Amphiphile (AMP) platform. This news page aggregates company press releases and market-moving updates related to Elicio’s clinical programs, platform research, and corporate developments.
Recent news from Elicio has focused on its lead program ELI-002, an AMP-based, off-the-shelf immunotherapy targeting cancers driven by KRAS mutations. The company regularly reports immunogenicity data from the Phase 2 AMPLIFY-7P trial in mKRAS pancreatic ductal adenocarcinoma, including mKRAS-specific T cell response rates, CD4 and CD8 activation, antigen spreading to non-mKRAS neoantigens, and analyses across diverse HLA backgrounds. These updates provide insight into how ELI-002 7P may elicit broad, mutation-directed immune responses in high-risk patients.
In addition to clinical readouts, Elicio’s news flow includes announcements about preclinical findings for intratumoral ELI-004, presentations at scientific meetings such as the Society for Immunotherapy of Cancer and ESMO Immuno-Oncology Congress, and investigator-initiated trials combining ELI-002 7P with chemotherapy and checkpoint inhibitors in pancreatic cancer. Corporate updates, including financial results, cash runway commentary, and executive appointments, also feature prominently in the company’s disclosures.
Investors and observers following ELTX news can use this page to review Elicio’s latest statements on its AMP platform, off-the-shelf immunotherapy strategy, and development plans in mKRAS-positive pancreatic and colorectal cancers, as well as emerging programs targeting BRAF and p53 mutations. Bookmark this feed to monitor new trial data, regulatory-related communications, and other material events reported by the company.
Elicio Therapeutics (ELTX) reported Q3 2024 financial results and corporate updates. The company expects to complete enrollment in its AMPLIFY-7P Phase 2 randomized study in Q4 2024, with interim analysis expected in H1 2025. Q3 financial results showed R&D expenses of $7.2 million and G&A expenses of $3.1 million. Net loss was $18.8 million, with cash position of $26.0 million as of September 30, 2024. The company strengthened its financial position through an $11.5 million public offering and $20 million private placement of convertible notes, expecting to support operations into Q2 2025.
Elicio Therapeutics presented updated preliminary results from the AMPLIFY-7P Phase 1 clinical trial of ELI-002, an Amphiphile cancer vaccine targeting KRAS-mutant tumors. Key findings show mKRAS-specific T cell responses in all evaluable patients, with the 4.9 mg dose group showing 12-fold higher response than the 1.4 mg group. The magnitude of T cell response correlated with disease-free survival (DFS). T cell responses were durable up to 1.5 years, with antigen spreading detected in 100% of RP2D-treated patients. The vaccine remains safe and well-tolerated, with Phase 2 interim DFS analysis expected in H1 2025.
Elicio Therapeutics (Nasdaq: ELTX) announced two upcoming presentations in November 2024. At the SITC 39th Annual Meeting (Nov 6-10), they will present updated T cell and Disease-Free Survival data from the AMPLIFY-7P Phase 1 trial of ELI-002, an Amphiphile cancer vaccine targeting KRAS-mutant tumors. The Phase 2 portion of this trial is ongoing with enrollment expected to complete in Q4 2024. Additionally, at the Stand Up To Cancer Innovation Summit (Nov 4), Dr. Peter Demuth will present updates on the AMP platform and data from both AMPLIFY-7P and AMPLIFY-201 Phase 1 trials.
Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company focused on developing novel cancer immunotherapies, has announced the granting of inducement stock options to two new employees. The grants, approved by the Compensation Committee of Elicio's Board of Directors, were made under the company's 2024 Inducement Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The details of the grants are as follows:
- Total options granted: 5,900
- Grant date: October 15, 2024
- Exercise price: $4.49 per share (closing price on grant date)
- Vesting schedule: 25% after one year, remainder vesting monthly over the following three years
These stock options serve as an inducement for the new employees joining Elicio Therapeutics and are subject to their continued employment with the company.
Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotech company focused on cancer immunotherapies, has announced the granting of 4,800 inducement stock options to a new employee. This grant, approved by the Compensation Committee of Elicio's Board of Directors, was made under the company's 2024 Inducement Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options allow for the purchase of Elicio common stock at $4.13 per share, which was the closing price on September 16, 2024, the date of grant. The options have a four-year vesting schedule, with 25% vesting on the first anniversary of the employee's start date and the remainder vesting monthly thereafter, contingent on continued employment with Elicio.
Elicio Therapeutics (Nasdaq: ELTX) announced three upcoming presentations focusing on its lymph node targeted, mKRAS-specific Amphiphile vaccines. The presentations will take place at:
1. AACR Special Conference (Sept 15-18, 2024, Boston): Dr. Eileen O'Reilly will present Phase I AMPLIFY-7P trial updates.
2. RAS-Targeted Drug Development Summit (Sept 25, 2024, Boston): Dr. Pete DeMuth will discuss clinical translation of Elicio's RAS-targeted Amphiphile vaccines.
3. Stuart and Molly Sloan Precision Oncology Institute Symposium (Oct 1, 2024, Seattle): Dr. Christopher Haqq will present Phase I experience with ELI-002 2P and ELI-002 7P.
CEO Robert Connelly highlighted recent data showing T cell response correlation with reduced tumor biomarkers and progression risk. Elicio's $43 million funding is expected to provide runway into Q2 2025, with clinical updates expected in Q4 2024 and Q1 2025.
Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotech company developing novel immunotherapies for cancer treatment, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. CEO Robert Connelly will present on September 11, 2024, at 2:30 p.m. ET. The presentation will be available via live webcast and on-demand for 90 days afterward.
Elicio specializes in lymph node-targeted immunotherapies using their proprietary AMP technology. This approach aims to enhance the immune system's cancer-fighting capabilities by delivering therapeutic payloads directly to lymph nodes. Their R&D pipeline includes off-the-shelf therapeutic cancer vaccines ELI-002 (for mKRAS-driven cancers), ELI-007, and ELI-008 (for BRAF-driven cancers and p53 hotspot mutations, respectively).
Elicio Therapeutics (Nasdaq: ELTX) reported Q2 2024 financial results and provided corporate updates. Key highlights include:
- AMPLIFY-7P Phase 1 data showed 100% of patients developed mKRAS-specific T-cell responses
- Phase 2 randomized trial of ELI-002 expected to complete 135-patient enrollment in Q4 2024
- $43 million raised in 2024, funding operations into Q2 2025
- Q2 2024 R&D expenses increased to $8.2 million from $4.9 million in Q2 2023
- Net loss for Q2 2024 was $7.2 million or $0.64 per share
- Cash and equivalents as of June 30, 2024 were $3.4 million, not including $29.6 million in subsequent financings
Elicio Therapeutics (Nasdaq: ELTX) has announced the closing of a $20.0 million private placement of a 3.0% Senior Secured Convertible Promissory Note due February 15, 2026. The note was purchased by GKCC, , an entity controlled by an Elicio board member. Key details include:
- Initial conversion price: $5.81 per share (135% of closing price on August 9, 2024)
- Interest: 3% per annum, payable quarterly in cash
- Maturity date: February 15, 2026
- Use of proceeds: Working capital and general corporate purposes
The convertible note is secured and senior to other obligations. Elicio granted customary registration rights for shares issuable upon conversion. This private placement was conducted under Section 4(a)(2) of the Securities Act of 1933.
Elicio Therapeutics (Nasdaq: ELTX) has announced the pricing of an $11.5 million public offering. This includes 500,000 shares of common stock and warrants to purchase another 500,000 shares at $5.00 per share, as well as pre-funded warrants for 1,800,000 shares at an exercise price of $0.01 each, with accompanying warrants also priced at $5.00 per share.
The offering is expected to close by July 1, 2024, subject to customary conditions. The funds will support Elicio's development pipeline, working capital, and general corporate purposes. JonesTrading Institutional Services is the sole book-running manager.